Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Explore this paper's citation graph
Summary
These studies discovered small molecules that bind with drug-like potencies to 'hotspots' on the contact surfaces involved in protein–protein interactions, and bind with much higher efficiencies than do the contact atoms of the natural protein partner.
- Type
- review
- Published
- 2007-12-12
- Cited by
- 1,856
- References
- 100
- Access
- Open access
- OpenAlex
- https://openalex.org/W2056169996
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205211934
Keywords
Small molecule, Drug discovery, Protein–protein interaction, Drug, Computational biology
References
- EVIDENCE FOR CONFORMATION CHANGES INDUCED BY SUBSTRATES OF PHOSPHOGLUCOMUTASE.
- Phage display for selection of novel binding peptides.
- The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.
- The Bcl-2 protein family: arbiters of cell survival.
- Discovery of a potent small molecule IL-2 inhibitor through fragment assembly.
- Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
- Druggability indices for protein targets derived from NMR-based screening data.
- Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity.
- Solution structure and dynamics of the complex between cytochrome c and cytochrome c peroxidase determined by paramagnetic NMR
- Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein–protein complexes
- Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin
- Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
- Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2
- Exploring protein-ligand recognition with Binding MOAD.
- Protein-protein interactions as targets for small molecule drug discovery.
- Space-filling models of kinase clefts and conformation changes.
- Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
- Fragment-based lead discovery: a chemical update.
- The structure of a yeast hexokinase monomer and its complexes with substrates at 2.7-A resolution.
- Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B.
Cited by
- The Role of Protein Structural Analysis in the Next Generation Sequencing Era
- Escaping amyloid fate
- Two 'Golden Ratio' indices in fragment-based drug discovery.
- Mechanisms of protein kinase A anchoring.
- Protein epitope mimetics as anti-infectives.
- Computational approach to de novo discovery of fragment binding for novel protein states.
- Integration of cell‐free protein coexpression with an enzyme‐linked immunosorbent assay enables rapid analysis of protein–protein interactions directly from DNA
- Yeast two-hybrid methods and their applications in drug discovery.
- The impact of plant-pathogen studies on medicinal drug discovery.
- Predicting and characterising protein-protein complexes
- Counterbalance of ligand‐ and self‐coupled motions characterizes multispecificity of ubiquitin
- Inhibition and stabilization of protein-protein interactions. Preface.
- Targeting protein-protein interaction by small molecules.
- Small Molecule Inhibition of CD40–CD154 Co-stimulatory Interaction
- Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
- Neutralizing endogenous chemokines with small molecules
- Divergent approach to building a latrunculin family derived hybrid macrocyclic toolbox.
- Spray drying formulation of amorphous solid dispersions.
- Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors
- INTerface Builder: A Fast Protein-Protein Interface Reconstruction Tool
Related papers
- The modular approach to ligand discovery.
- Antibody-enabled small-molecule drug discovery
- Finding Small Molecule Ligands for Protein-Protein Interactions and Other “Undruggable” Targets
- RNA‐Selective Small‐Molecule Ligands: Recent Advances in Live‐Cell Imaging and Drug Discovery
- Nature Inspired Small Molecules for Chemical Biology
- Current Status and Strategy of Middle-Molecule Drug Discovery
- Target-oriented and diversity-oriented organic synthesis in drug discovery.
- Design of Tracers in Fluorescence Polarization Assay for Extensive Application in Small Molecule Drug Discovery.
- Considerations of the chemical biology of microbial natural products provide an effective drug discovery strategy
- Protein–protein interactions as targets for small-molecule therapeutics in cancer